Forest Laboratories, Inc. (FRX) announced that the U.S. Food and Drug Administration's or FDA Anti-Infective Drugs Advisory Committee voted 21 - 0 in favor of approval of ceftaroline fosamil.
Ceftaroline Fosamil was approved for the treatment of community acquired bacterial pneumonia or CABP and voted 18 - 0 in favor of approval for complicated skin and skin structure infections or cSSSI, the company noted.
Commenting about Ceftaroline, the company said it is a novel, bactericidal, broad-spectrum injectable cephalosporin shown in pre-clinical and clinical trials to have activity against both gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae, and common gram-negative pathogens.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.